Hesco Class 1 new drugs are about to be approved for a $10 billion market for narcotic drugs

recently, Hesco's class 1 new drug HSK3486 emulsion market application entered the approval status, will soon be approved for market. It is reported that the product is intended to be used for surgical all-hemp induction, endoscopic treatment of sedation / anesthesia, ICU sedation and other adaptive disorders, this is expected to be approved by the company in 2019 declared the adaptive, digestive endoscopy diagnosis and treatment of sedation and/or anesthesia (acceptance number: CXHS190020).According to the Hesco announcement, HSK3486 emulsion is the company developed a new intravenous anesthetic drug with independent intellectual property rights, intended for surgical whole hemp induction, endoscopy sedatives / anesthesia, ICU sedation and other indications, drug registration classified as chemical drugs 1 category.HSK3486 obtained the Drug Clinical Trial Approval issued by NMPA in January 2016 to initiate a clinical trial of "Digestive endoscopic diagnosis and treatment of sedation and/or anesthesia" adaptation, and the application for the new drug was accepted in July 2019 (acceptance number: CXHS1) 900020), which was included in the priority review in August of the same year, and in January 2020 NMPA accepted the application for a new drug for the product's "general anaesthetic induction" allergy (acceptance number: CXHS2000001), which was included in the priority review in February of the same year. At present, the product's "full hemp maintenance" adaptive clinical application has been approved, "sedative during intensive care" adaptive clinical application in the review and approval.In China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal nervous system drug market, sales of narcotic drugs have exceeded 16 billion yuan, the growth rate in 2018-2019 remained above 10%, the first half of 2020 affected by the epidemic patients reduced the frequency of surgery, the growth rate fell by 15%.So far in 2020, five new products in the 10 billion-dollar market have been approved for market, of which only two are new (Hengrui announced on January 3, 2020 that the injection of toluene sulfonate has been approved for listing), and if Hesco's HSK3486 emulsion is successfully approved, it is expected to become the third new class of drugs to be marketed this year. (Mi net
)